Представлено обоснование разработки пероральной лекарственной формы на основе сухого экстракта травы зюзника европейского. Исследован рынок лекарственных препаратов, применяющихся для лечения заболеваний щитовидной железы. Проведено анкетирование среди трех групп респондентов.
Pharmaceutical market for drugs used in the prevention and treatment of diseases of the thyroid gland studied. The structure of the market of drugs in this therapeutic group defined. Investigational drugs are available in the following dosage forms: tablets, chewable tablets and tablets covered with a film cover. Most drugs registered and used in Russia, affecting the thyroid gland, are produced in Germany.Among registered drugs affecting the thyroid herbal medications are not available. During our studies, with the use of designed for these purposes, the questionnaire identified the segment of consumers of drugs in this group. It is mostly women aged 20 to 55 years.The study of three groups of respondents: physicians, pharmaceutical professionals and consumers on the method of questioning conducted. Respondents were asked about what dosage forms are the most convenient to use; what drugs have the least amount of side effects and about the prospects of developing a new drug from medicinal plants. The study identified the main characteristics that must be met drug thyroid-stimulating actions in oral dosage form, taking into account the origin and presence of side effects depending on the drug substance.The relevance of developing a new Russian herbal drug in the form of oral dosage forms (tablets and capsules) based on the dry extract of Bugleweed European on the basis of All-Russian Institute of Medicinal and Aromatic Plants (VILAR) justified. Therapeutic effect due to the presence in the grass of Bugleweed European and dry extract from this medicinal plant materials o-dihydroxyphenyl: derivatives of caffeic acid and flavonoids, the main component of the sum of-dihydroxyphenyl is rosmarinic acid.